Mar 06, 2020 6:09am EST Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus
Feb 26, 2020 6:00am EST Algernon Pharmaceuticals to be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
Feb 21, 2020 6:00am EST Algernon Pharmaceuticals Announces Increase and Closing of CDN$1.55M Private Placement
Feb 07, 2020 6:00am EST Algernon Pharmaceuticals Appoints Professor of Respiratory Medicine Dr. Jacky Smith to Its Medical and Scientific Advisory Board
Jan 17, 2020 6:00am EST Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment
Dec 16, 2019 6:00am EST Algernon Pharmaceuticals Appoints Leading Respirologist Dr. Martin Kolb to Its Medical and Scientific Advisory Board
Dec 10, 2019 6:00am EST Algernon Pharmaceuticals to Present at 12th Annual LD Micro Main Event Conference on Wednesday December 11, 2019
Dec 09, 2019 6:00am EST Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough
